Introduction
============

Hemizygous deletions in chromosome 22q11.2 occur predominately *de novo* and cause a deletion syndrome (22q11.2DS), characterized by a broad spectrum of physical and mental manifestations with a variable phenotype. The syndrome has an incidence of 1 in 2000--4000 live births. The physical phenotype is characterized by variably penetrant craniofacial and cardiovascular anomalies, immunodeficiency, short stature and hypocalcaemia. Furthermore, deletion carriers typically present with a range of behavioural and cognitive deficits and 25--30% develop schizophrenia during adolescence or early adulthood.^[@bib1]^ 22q11.2 deletions account for 1--2% of sporadic schizophrenia cases, exemplifying the role of rare mutations in disease susceptibility. Importantly, there are no major clinical differences in the core schizophrenia phenotype between individuals with schizophrenia who are 22q11.2 microdeletion carriers and those with an idiopathic disease onset.^[@bib2]^ A 1.5-Mb critical region, which confers haplo-insufficiency of 27 genes,^[@bib3],\ [@bib4]^ including the candidate schizophrenia susceptibility genes (proline dehydrogenase (*PRODH*), catechol-O-methyltransferase (*COMT*) and DHHC palmitoyltransferase (*ZDHCC8*)), is largely conserved on mouse chromosome 16. This has facilitated generation of mouse models of the human 22q11DS, carrying hemizygous deletions in the syntenic region of chromosome 16. One of the best characterized models is the *Df(16)A*^*+/−*^ mouse, which carries a hemizygous 1.3-Mb chromosomal deficiency on chromosome 16 (*Df(16)A*), encompassing 27 genes, which is syntenic to the minimal 1.5-Mb human 22q11.2 deletion.^[@bib5]^ These mice develop deficits in spatial working memory, sensorimotor gating and fear conditioning as well as presenting with hyperactive behaviour.^[@bib5],\ [@bib6]^ In addition, they show abnormalities in synaptic connectivity of hippocampal and cortical neurons, including a lower density of dendritic spines and glutamatergic synapses and altered synaptic plasticity.^[@bib7]^

Studies that have examined the effect of *Df(16*)*A* on transcriptional networks revealed downregulation of microRNA (miRNA) transcripts,^[@bib5],\ [@bib8]^ resulting from the combined effect of two disrupted genes (*Dgcr8* and miR-185) in the critical region. *Dgcr8* hemizygosity leads to dysregulation in the production of up to 20% of all miRNAs, while miR-185 levels are reduced by 70--80% owing to a combined effect with the *Dgcr8* hemizygosity,^[@bib9]^ which leads to an impaired maturation of the pri-miR-185 transcript. Based on the transcriptional profiling, the most robust miRNA target was a novel neuronal regulatory gene *2310044H10Rik/Mirta22*, which was confirmed to be specific for miR-185 and has been followed up in functional studies. It was shown that this gene encodes a protein, which is located in the Golgi apparatus and in vesicles and tubular-like extensions of dendrites, mediating at least some of the effects of the 22q11.2 deletions on dendrite and spine formation.^[@bib10]^

To date, no other direct miRNA targets have been reported for the 22q11.2DS and it is still not known how the reported transcriptomic^[@bib5],\ [@bib11]^ alterations affect cell biology at the proteomic and metabonomic level. In the disease pathology, proteomic and metabonomic networks are likely to be regulated through the combined interactions of the 22q11.2 deletion gene products, which involve the hemizygosity of four transcription factors and disruption of miRNA-regulated targets. This may involve dysregulation of other transcription factors, chromosome remodelling elements or changes in the expression of signalling proteins. Also, secondary compensation effects might have a role. Here we have carried out a combined shotgun proteomic and metabonomic profiling analysis of brain tissue from *Df(16)A*^*+/−*^ mice to investigate the combined effects of miRNA dysregulation and disruption of genes residing in the 22q11.2 region. Our results provide novel insights towards a better understanding of the molecular pathophysiology of psychiatric disorders and cognitive dysfunction.

Materials and methods
=====================

For more detailed information, please refer to [Supplementary Methods](#sup1){ref-type="supplementary-material"}. A flowchart of the molecular profiling methods can be found in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}.

Animals
-------

The *Df(16)A*^+/−^ mice were produced and bred at Columbia University (New York, NY, USA) as described previously.^[@bib5]^ Eight-week-old male mice were used for the analyses. Mutant mice carry a hemizygous 1.3-Mb chromosomal deficiency (*Df(16)A*^+/−^), which ranges from *Dgcr2* to the *Hira* gene and encompasses a segment syntenic to the 1.5-Mb human 22q11.2 deletion, including 27 protein-coding genes. All animal procedures were performed according to protocols approved by the Columbia University Institutional Animal Care and Use Committee under federal and state regulations.

Multiplex immunoassay profiling
-------------------------------

Serum samples from 11 *Df(16)A*^+/−^ and 10 *wild-type* mice (cohort 1) were analysed randomized and blinded using a multianalyte profiling platform, comprising multiplexed immunoassays for 58 analytes ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) in a Clinical Laboratory Improved Amendments (CLIA)-certified laboratory at Myriad-RBM (Austin, TX, USA) as described previously.^[@bib12],\ [@bib13]^ Data quality was assessed via principal component analysis (PCA), data were checked for normality and significance analysis of mircroarray^[@bib14]^ was performed.

Metabonomics
------------

Metabonomic sample preparation and profiling of prefrontal cortical (PFC) and hippocampal (HPC) tissues from 11 *Df(16)A*^+/−^ and 10 *wild-type* mice (cohort 1) was performed as described previously.^[@bib15]^ In brief, tissue samples were prepared using a two-step process based on extraction into 'aqueous\' and 'organic\' phases for polar and nonpolar metabolites. Quality-control samples were prepared by combining an aliquot from each study sample to produce a representative sample, which was used for column conditioning and data quality assessment as described by Want *et al.*^[@bib15]^ Aqueous extracts were analysed via nano-ultra-performance liquid chromatography--mass spectrometry (UPLC-MS) analysis using a Waters XEVO G2 Q-TOF mass spectrometer coupled online to an Acquity UPLC-MS system (Waters, Milford, MA, USA). Metabolites were separated using a 2.1 × 100 mm^2^ (1.7 μm) HSS T3 Acquity column, and acquisition was performed in both positive ion mode and negative ion mode. Quality-control samples were injected 10 times at the start of the analytical batch in order to condition the column, and then after every 10 samples throughout the run to assess instrument stability. Samples were run randomized and blinded. Data were processed using the freeware XCMS^[@bib16],\ [@bib17]^ using standard parameters. The output consisted of a matrix of metabolite feature *m*/*z*, retention time and intensity values, which was imported into SIMCA-P for multivariate analysis to check data quality and sample outliers. Data were normalized, filtered and checked for normality prior statistical analysis. *P*-values were determined using Wilcoxon\'s signed-rank test and corrected to control for multiple hypothesis testing (Benjamini--Hochberg).^[@bib18]^ Ratios were calculated for each analyte as the mean intensity values of *Df(16)A*^+/−^ mice divided by those of *wild-type* littermates.

Proteomics
----------

For more detailed information, please refer to [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

Sample preparation and study design
-----------------------------------

PFC and HPC brain tissues from *Df(16)A*^*+/−*^ and *wild-type* mice were prepared using total lysis protein extraction^[@bib19],\ [@bib20]^ combined with either in-solution (two independent cohorts; cohort 1 (PFC and HPC): 11 *Df(16)A*^*+/−*^ vs 10 *wild-type* mice, cohort 2 (PFC): 13 *Df(16)A*^*+/−*^ vs 13 *wild-type* mice) or in-gel tryptic digestion ((PFC): 20 *Df(16)A*^*+/−*^ and 21 *wild-type* mice, combined from both cohorts to increase statistical power, proteome coverage and avoid sample extraction biases). Samples were subsequently analysed using label-free LC-MS^E^ mass spectrometry, enabling unbiased protein identification and quantification. Mass spectrometrical sample preparation, label-free LC-MS^E^ analysis and selected reaction monitoring (SRM) analysis were performed blinded and randomized. Sample size was chosen based on previous experiments using FC and HPC brain tissues and proteomic guidelines. In all, 8--10 animals per group are sufficient for the proteomic shotgun discovery phase. Power calculations using MSstats showed that to achieve a fold change of 15% with 0.8 power 10 sample are needed. The validity of the results was further proven in 20 *Df(16)A*^*+/−*^ and 20 *wild-type* mice using highly sensitive and robust label-based SRM mass spectrometry.

Label-free LC-MS^E^ analysis of PFC and HPC tissue
--------------------------------------------------

Brain tissue samples were analysed individually in technical duplicates using a splitless UPLC (10 kpsi nanoAcquity; Waters) coupled online to a Waters Q-TOF Premier mass spectrometer. Data were acquired in expression mode (MS^E^). The procedure, quality assessment and data processing were performed as described previously.^[@bib21]^ LC-MS^E^ data were processed using the ProteinLynx Global Server (PLGS) v.2.4. (Waters) and Rosetta Elucidator v.3.3 (Rosetta Biosoftware, Seattle, WA, USA) was used for time and mass/charge alignment of mass spectrometric data. The Swiss-Prot mouse reference (March, 2013) proteome was used for protein identification searches. Only peptides detected in both replicates and in \>80% of samples were included in further analysis. Protein abundance changes were determined using the MSstats package^[@bib22]^ based on linear mixed-effects models, which views peptides mapped to the same protein as replicate measurements of protein abundance, following log~2~ transformation and exclusion of peptide intensity values that were \>3 s.d. from the mean of each group. The MSstats package included quality assessment and PCA on the raw data was carried out to detect data outliers. The *P*-values were adjusted to control the false-discovery rate at a cutoff of 0.05 following the Benjamini--Hochberg procedure.^[@bib23]^

Label-based SRM mass spectrometry
---------------------------------

Digested FC and HPC proteomes (20 *Df(16)A*^*+/−*^ and 20 *wild-type* mice), prepared using in-solution digestion from total lysates, were analysed using targeted SRM mass spectrometry on a Xevo TQ-S mass spectrometer (Waters) coupled to a nanoAcquity UPLC system (Waters) as described previously.^[@bib13],\ [@bib20],\ [@bib24]^ Multiplex SRM assays were developed using a high-throughput strategy.^[@bib25]^ Physiochemical criteria for selecting tryptic peptides were based on peptide count, uniqueness and quality of transitions. Transitions were selected based on software internal predictions, discovery proteomics data and spectral data (NIST spectral libraries^[@bib26]^) and calculated using Skyline version 1.2.0.3425.^[@bib27]^ Quantitative SRM measurements comparing abundance levels of 40 proteins between *Df(A)16*^+/−^ mice and *wild-type* littermates were performed in scheduled SRM acquisition mode. Heavy isotope labelled peptide versions (JPT Peptide Technologies, Berlin, Germany) were spiked in the peptide mixture for accurate quantification and identification. For each peptide, at least three transitions were monitored for the heavy and light versions. The final transitions can be found in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}. Samples were run blinded, randomized and blocked^[@bib28]^ in triplicates, and blanks and quality-control peptide injections (yeast alcohol dehydrogenase)^[@bib24]^ were run alternating after each biological replicate. Resulting SRM data were analysed using Skyline and statistical analysis, testing for differential abundance among *Df(A)16*^+/−^ and *wild-type* mice, was conducted using SRMstats^[@bib23]^ with the 'expanded technical replication\' setting. Data quality was checked using quality plots in the MSstats package and by employing PCA on the raw data. *P*-values were corrected to control for multiple hypothesis testing (Benjamini--Hochberg).^[@bib18]^

Results
=======

Serum characterization---quantitative serum immunoassay profiling
-----------------------------------------------------------------

Immunodeficiency is one of the key features of the 22q11.2DS, but the degree and spectrum of severity varies widely. A large number of studies have provided evidence suggestive of an immunological component of schizophrenia^[@bib29]^ and other psychiatric disorders.^[@bib30],\ [@bib31]^ We hypothesized that immune dysfunction, as reflected in the levels of immune and metabolic circulation markers, may contribute to the elevated risk of schizophrenia in the 22q11.2DS.^[@bib32]^ Analysis of 58 such markers ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}) in the serum of the *Df(16)A*^+/−^ mouse using a multiplex immunoassay platform resulted in the identification of a significant decrease in matrix metalloproteinase 9 (MMP-9; ratio=0.74, *P*=0.039, *P\*=0.20*) in the *Df(16)A*^+/−^ (*n*=11) compared with *wild-type* (*n*=10) mice.

Brain characterization---quantitative proteomics
------------------------------------------------

In the proteomic discovery phase, shotgun profiling of PFC and HPC tissue was carried out to identify proteins differentially expressed in the *Df(16)A*^+/−^ mouse model compared with *wild-type* mice. The main aim was to identify affected protein networks that might contribute to the development of psychiatric and cognitive phenotypes in the 22q11.2DS, as well as novel miR-185 targets. We focused on the PFC and HPC because these brain regions have previously been characterized at the transcriptomic level^[@bib5],\ [@bib11]^ and are implicated in the pathology of various psychiatric disorders. Special emphasis was placed on the PFC as the most extensively characterized brain region in the *Df(16)A*^+/−^ mouse.^[@bib5],\ [@bib11]^ Total lysis extracts from PFC tissues of two independent cohorts of *Df(16)A*^+/−^ mice (11 *Df(16)A*^+/−^ vs 10 *wild-type* / 13 *Df(16)A*^+/−^ vs 13 *wild-type*) were analysed, as well as from the HPC of one of the cohorts (11 *Df(16)A*^+/−^ vs 10 *wild-type*). Additionally, PFC tissue of both cohorts were combined (*n*=40) and prepared with a different gel-based procedure to increase proteome coverage and statistical power. Shotgun profiling analysis resulted in the identification of 578 distinct proteins (9605 peptides) in the PFC (cohort 1) of which 59 proteins showed significant genotypic differences (*P\*\<*0.05). Likewise, 715 distinct proteins (14 334 peptides) (cohort 2) were identified in cohort 2, with 186 proteins showing abundance differences between genotypes. In total, 552 distinct proteins (11 193 peptides) were identified in the combined cohorts and 104 of these had significantly changed protein levels. In the HPC, we identified 570 distinct proteins (8934 peptides) of which 63 were significantly different in the mutant mice ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

In order to identify robust alterations of *Df(16)A*^*+/−*^ hemizygosity, we cross-compared all proteomic profiling studies among each other and to previous transcriptomic profiling studies^[@bib5],\ [@bib11]^ of the *Df(16)A*^+/−^ mice ([Figure 1a](#fig1){ref-type="fig"}). Most consistently, we found an average decrease of 20% in septin 5 levels ([Figure 1d](#fig1){ref-type="fig"}), a protein encoded in the 22q11.2DS critical region. In the case of other 22q11.2DS encoded proteins, we detected a reduction in the levels of protein DGCR14 (ES2EL) (ratio=0.85, *P*=8.2 × 10^−6^, 1 peptide) in one of the proteomic cohorts. We further detected a 30% increase in the levels of the hypoxanthine-guanine phosphoribosyltransferase (HPRT) in the *Df(16)A*^+/−^ mice. Two mini-cassettes of the *Hprt* gene are part of the viral transfection vector where they serve as a positive selection marker for successful recombination and deletion of the 22q11.2 critical region. The identified changes in these proteins substantiate the technical robustness of our proteomic platform. All other 22q11.2DS-encoded proteins, which could serve as positive controls, were below the detection limit, probably owing to low or absent expression in the brain.^[@bib33]^

Other identified proteins, which showed alterations in abundance, are either primary or secondary effects of abnormal miRNA metabolism or hemizygosity of 22q11.2 genes. For example, we identified a decrease in glutathione *S*-transferase Mu7 (GSTM7) in three of the proteomic studies, which could be a secondary effect of the *Txnrd2* (thioredoxin reductase 2) hemizygosity. Both proteins have been implicated in the regulation of the intracellular redox environment.^[@bib34],\ [@bib35],\ [@bib36],\ [@bib37]^ Furthermore, we discovered robust decreases of mitochondrial proteins (cytochrome *c* oxidase subunit 5B, mitochondrial (COX5B), NADH-ubiquinone oxidoreductase chain 4 (NU4M)). A possible reason for these alterations is the involvement of several 22q11.2 genes (*Prodh*, *Comt*, *Txtp*, *Slc25a1*) in mitochondrial function. Indeed, using the IPA software, we confirmed that 'mitochondrial dysfunction\' was a common pathway affected across all profiling studies ([Figure 1c](#fig1){ref-type="fig"}).

In order to identify proteins that might be upregulated owing to miR-185 hemizygosity, we analysed all upregulated detected proteins using bioinformatic miRNA target prediction tools (MirDB, Targetscan, MirBase, DIANA), which were based on thermodynamics (DIANA), seed complementarity (Targetscan) or support vector machines (MirDB). Potential miR-185 targets are disk large homolog 2 (DLG2), AP2-associated protein kinase 1 (AAK1), sodium/potassium-transporting ATPase subunit alpha-3 (AT1A3), O-GlcNAc transferase subunit p110 (OGT1) and protein bassoon (BSN), which were found to be upregulated at the proteomic and transcriptomic levels.^[@bib5]^

We were not able to identify a significant increase in sarcoplasmatic/endoplasmic reticulum calcium ATPase 2 (SERCA2---*Atp2a2*), another recently proposed target of 22q11.2DS-associated miRNA dysregulation,^[@bib38]^ in any of our proteomic screens. This is consistent with Fenelon *et al.*,^[@bib11]^ who failed to confirm a change in the transcript and protein levels of *Atp2a2*.

Remarkably, the differentially expressed proteins showed an overall increase in abundance levels across all FC proteomic studies ([Figure 1b](#fig1){ref-type="fig"}), which is likely owing to a decrease in about 20% of the miRNAs^[@bib5]^ (including miR-185) and subsequent upregulation of targets. This finding is consistent with the transcriptomic profiling study by Fenelon *et al.*^[@bib11]^ On the other hand, the HPC proteome showed a trend towards downregulation of differentially expressed proteins. Because of the lack of replication studies, further confirmation of the opposing changes in the HPC is needed. Nevertheless, the results are consistent with reported miRNA changes in PFC and HPC identified through transcriptomic profiling, as nearly twice the number of miRNAs were found to be decreased in the PFC (59 miRNAs) than in the HPC (30 miRNAs).^[@bib5]^

*In silico* analysis revealed an overrepresentation of developmentally regulated pathways related to nucleosome and chromatin assembly and chromatin-level regulation across all PFC proteomic studies ([Figure 2](#fig2){ref-type="fig"}). Further pathway analysis using the IPA software allowed us to identify overlaps between canonical pathways. The proteomic alterations were associated with the canonical pathways 'glycolysis I\', 'gluconeogenesis\' and 'mitochondrial dysfunction\' ([Figure 1c](#fig1){ref-type="fig"}) in the PFC and 'Rho signalling\' in the HPC, which was also reflected in the enrichment analysis.

Brain characterization---quantitative metabonomics
--------------------------------------------------

We next carried out metabonomic profiling of PFC and HPC tissues from the *Df(16)A*^*+/−*^ mouse in order to determine whether the above changes in proteins could be linked to alterations in metabolites. Therefore, after the initial identification of a metabolite candidate, the sample was re-run and the peaks were subjected to fragmentation in an MS/MS experiment. Identification of a specific metabolite was accomplished though comparison of the fragmentation pattern of a candidate metabolite with the known MS/MS fragmentation pattern in public and in-house databases. This analysis showed significant changes in 21 *m*/*z*-retention time pairs in the PFC, and we were able to identify 7 of these metabolites via MS/MS fragmentation. In the HPC, we detected 27 significantly changed *m*/*z*-retention time pairs, which we could match to 12 metabolites using metabolome databases and identified 4 via MS/MS fragmentation ([Table 1](#tbl1){ref-type="table"}, [Supplementary Table S5](#sup1){ref-type="supplementary-material"}). The most significant change in the PFC was a decrease in ceramide phosphoethanolamine (SP0302), which is a sphingomyelin analog. SP0302 may be linked to the hemizygosity of the ZDHHC8 palmitoyltransferase in the *Df(16)A*^+/−^ mouse, as palmitoyl-CoA is a precursor in the ceramide synthesis. Alongside, further ceramides were found to be decreased in the PFC and S-palmitoyl-L-cysteine was decreased in the HPC. In the HPC, we also found that sphingomyelin (SM(d17:1/24:1) was the most significantly increased metabolite (ratio=1.72, *P*=0.031). We were able to validate sphingomyelin\'s databank identification using tandem MS/MS. We detected changes in further lipids such as phosphatidylcholines and glycerolipids, which reflect the changes in lipid metabolism found in the proteomic pathway analysis of *Df(16)A*^+/−^ mice ([Figure 2](#fig2){ref-type="fig"}). In addition, several carnitines, which have a role in fatty acid metabolism, were found to be decreased ([Table 1](#tbl1){ref-type="table"}). Furthermore, proteomic abnormalities in aromatic amino acids could be confirmed via metabonomic profiling, detecting changes in different tyrosine derivates in both regions (*N*-stearoyl tyrosine and metyrosine). Although we were not able to validate the identification of these metabolites using MS/MS, their changes were reflected in the protein set enrichment analysis of the HPC 'aromatic amino-acid family metabolic process\'. A decrease in panthothenic acid---essential in the synthesis of coenzyme-A (CoA)---was also reflected in the proteomic pathway analysis with CoA biosynthesis being affected in cohort 1, where we found increased levels of two of the key enzymes in this pathway.

Proteomic validation
--------------------

We developed highly specific and sensitive targeted SRM assays in order to follow-up and validate alterations identified in the proteomic discovery phase. We assayed for potential miRNA targets (OGT1, ADA10) as well as altered proteins identified in the LC-MS^E^ profiling approach (PP2BC, NRDC). The inclusion of the miR-185 targets was based on LC-MS^E^ analysis, bioinformatic predictions and the shotgun proteomics analysis-derived *in silico* pathway analysis. We further included 6 of the 27 22q11.2 gene products to determine whether or not the mRNA changes are reflected at the protein level and could serve as potential positive controls. The vesicular glutamate transporter 1 (VGLU1) was included based on evidence obtained from the transcriptomic screen where VGLU1 was one of the three transcripts found to be significantly upregulated in both PFC and HPC.^[@bib5]^ Unfortunately, we were not able to develop assays for DLG2 and BSN owing to assay design issues. We further extended the validation screen to include proteins of pathways that have been implicated in some of the major symptoms observed in 22q11.2DS. This included the mammalian target of rapamycin (mTOR) signalling pathway, which has been linked to autism-like behaviour, cognitive function and glutamatergic signalling. Details of the composition of the multiplex assay can be found in [Table 2](#tbl2){ref-type="table"}.

The SRM analysis ([Table 2](#tbl2){ref-type="table"}) validated the expected decrease in all the five tested 22q11.2 gene products and an increase of the HPRT peptides from the vector cassette, showing the technical robustness of the developed method. Importantly, SRM confirmed an increase in the miR-185-target OGT1 in PFC and HPC tissue. Alterations of OGT1 have been identified in the transcriptomics^[@bib5]^ and in proteomics ([Figure 1](#fig1){ref-type="fig"}) high-throughput screens of the PFC. The OGT1 enzyme exhibits protein *N*-acetylglucosaminyltransferase activity, which leads to attachment of O-GlcNAc onto intracellular proteins.^[@bib39]^ Furthermore, we were able to validate an increase in levels of the glycogen synthase kinase-3 beta (GSK3b) and kinesin heavy chain isoform 5A (KIF5A), a microtubule-dependent molecular motor that is important for neuronal functions especially for GABA~A~ receptor transport.^[@bib40]^ Similar to the transcriptomic and PROTEOMIC profiling analyses, we did not find altered levels of the miR-185 target transforming protein RhoA (RHOA). This might be due to secondary regulation caused by the hemizygous genes or downregulated miRNA that might involve alterations in transcriptional levels.

Further validated proteins were serine/threonine protein phosphatase 2B catalytic subunit gamma isoform (PP2BC), the neurofilament light polypeptide (NFL) and VGLU1. The latter was one of the only three proteins found in the transcriptomic screen in both PFC and HPC. The extracellular signal--regulated kinase (ERK) pathway was most significantly affected in the PFC, while abnormal glutamatergic signalling was predominately found in the HPC. The latter finding is consistent with published transcriptomic profiling results from the *Df(16)A*^+/−^ mice.^[@bib5]^

Discussion
==========

To the best of our knowledge, this study represents the first comprehensive quantitative proteomic and metabonomic characterization of a 22q11.2DS mouse model. We assume that the phenotype of this disease model is due to cumulative effects of abnormal miRNA regulation and hemizygosity of genes residing within the 22q11.2 chromosome region, which requires analysis on the systems level rather than by targeting the effects of individual genes.^[@bib41],\ [@bib42],\ [@bib43]^

Multiplex immunoassay profiling analysis identified altered serum levels of only one protein, the endopeptidase MMP-9, which has been implicated in many pathological conditions such as cancer, cardiovascular disease,^[@bib44]^ amyotrophic lateral sclerosis^[@bib45]^ and stroke.^[@bib46],\ [@bib47]^ Recently, MMP-9 has been reported to have a role in the plasticity of the central nervous system^[@bib48]^ by regulating the activity of PFC.^[@bib49]^ A functional polymorphism of the MMP-9 gene in schizophrenia^[@bib50]^ and bipolar disorder type II^[@bib51]^ has also been reported. The identified alterations might serve as surrogate readouts for the psychiatric comorbidities in the 22q11.2DS and help to elucidate the molecular mechanisms of the immunodeficiency in 22q11.2DS patients.

The proteomic brain profiling analysis revealed PFC and HPC changes in various molecular pathways associated with chromatin remodelling and RNA transcription, indicative of an epigenetic component of 22q11.2DS. Recently, it has been shown that developmentally regulated genes involved in chromatin remodelling are overrepresented among targets of *de novo* mutations in schizophrenia.^[@bib52],\ [@bib53]^ Therefore, this study highlights a possible contribution of chromatin remodelling in the manifestation of the psychiatric and cognitive phenotype in 22q11.2DS. Other associated pathways were glycolysis, gluconeogenesis, lipid biosynthesis and the mitochondrial transport chain. Effects on the latter two pathways were also reflected in the transcriptomic enrichment analysis of the *Df(16)A*^+/−^ mouse^[@bib5]^ and together with lipid metabolism have frequently been linked to psychiatric conditions.^[@bib54],\ [@bib55]^ Altered levels of sphingomyelin and ceramide have been reported in erythrocytes and postmortem brain tissues of schizophrenic patients.^[@bib56]^

Based on the proteomic and metabonomic findings, we created a schematic model summarizing the most prominent molecular network findings in the *Df(16)A*^+/−^ mouse. Interestingly, all implicated pathways can be linked through one of the most consistent and strongest proteomic candidates, (OGT1), which is a predicted miR-185 target ([Figure 3](#fig3){ref-type="fig"}).

OGT1 adds single terminal *N*-actylglucosamine (O-GlcNAc) residues to serine/threonine residues of specific target proteins.^[@bib39],\ [@bib57]^ This represents a crucial signalling modification relevant for cellular functions, such as epigenetic regulation, transcription activation processes,^[@bib58],\ [@bib59]^ chromatin remodelling,^[@bib60]^ translation, proteasomal degradation, signal transduction and stress responses.^[@bib61]^ Cellular substrates recognized by OGT1 are mostly present in macromolecular complexes, such as nuclear pores,^[@bib62],\ [@bib63],\ [@bib64],\ [@bib65]^ the transcriptional machinery^[@bib66],\ [@bib67],\ [@bib68]^ and vesicle docking components.^[@bib69],\ [@bib70],\ [@bib71],\ [@bib72]^ Consistently, we identified abnormalities in biological functions associated with these complexes in the *Df(16)A*^+/−^ brain and most of these were found in the PFC. Interestingly, we identified robust alterations of several histone proteins in the *Df(16)A*^*+/−*^ mouse model ([Figure 1d](#fig1){ref-type="fig"}). O-GlcNAcylation occurs on all four core-nucleosomal histone proteins (H2A, H2B, H3 and H4).^[@bib73]^ However, such chromatin and transcriptional-level abnormalities could also be due to the hemizygosity for four transcription factors (for example, Tbx1, Hira) in the *Df(16)A*^+/−^ mouse. Abnormalities in glycosylation have already been postulated to occur in the *Df(16)A*^+/−^ mouse by a bioinformatic enrichment analysis, which found coordinated dysregulation of Golgi-related putative miR-185 targets in the *Df(16)A*^+/−^ mouse.^[@bib9]^ Furthermore, the miR-185 target Mirta22 has been localized to the Golgi apparatus. This is the first study to suggest that changes in OGT activity may be linked to the above glycosylation alterations. This is also supported by the fact that *in silico* analysis of the 25 identified human OGT interacting proteins showed an enrichment of intra Golgi-vesicle-mediated transport and vitamin biosynthetic processes.^[@bib74]^ Also, bioinformatic analysis of an OGT-interactome substantiated the role of OGT in transcriptional regulation.^[@bib74]^ A potential role for O-GlcNAcylation in modifying synaptic efficacy and cognition has previously been suggested.^[@bib75]^ O-GlcNAcylation of AMPA receptors GluA2 has been linked to long-term depression in HPC synapses.^[@bib76]^ OGT1 is also involved in mitochondrial function,^[@bib77]^ consistent with the finding of alterations in the levels of mitochondrial proteins in this study. Overexpression of OGT1 leads to decreases in proteins involved in the respiratory chain and the TCA cycle,^[@bib77]^ as well as altered mitochondrial morphology. The majority of O-GlcNAc-modified proteins are soluble nuclear or cytoplasmic proteins that are modified in response to cellular or environmental cues, such as growth factors, signalling molecules, glucose and other nutrient fluxes and stressors. O-GlcNAcylation has also been implicated in the aetiology of human disorders, including type II-diabetes,^[@bib78]^ Alzheimer\'s disease^[@bib79]^ and cancer.^[@bib80]^ Notably, O-GlcNAcylation has also been shown to be a negative regulator of insulin signalling.^[@bib81]^ Transgenic mice overexpressing OGT in muscle and fat show elevated insulin levels and insulin resistance.^[@bib81],\ [@bib82]^ Interestingly, schizophrenia patients show an increased prevalence of diabetes, impaired glucose tolerance^[@bib83]^ and metabolic syndrome.^[@bib84]^ Similarly, molecular analyses of postmortem brain tissues and blood cells have substantiated these findings.^[@bib85],\ [@bib86],\ [@bib87]^ We also confirmed changes in GSK3beta and KIF5A, a microtubule-dependent molecular motor that is important for neuronal function, especially for GABA~A~ receptor transport.^[@bib40]^ In contrast, we did not find changes in the known miRNA target RHOA in any of the omics experiments. This might be due to the secondary effects of 22q11.2-encoded proteins. Further novel candidate miRNA targets implicated in both this and previous transcriptomic studies^[@bib5],\ [@bib9]^ include BSN, VAMP2, AAK1 and DLG2.

We were also able to validate the increased levels of PP2BC and NFL in the model. PP2BC is involved in synaptic plasticity and has already been shown to be associated with schizophrenia in genome-wide association studies,^[@bib88],\ [@bib89]^ via genome-wide DNA methylation analysis^[@bib90]^ and transcriptomic studies.^[@bib91]^ As PP2BC phosphorylates proteins on serine or threonine residues, it may have a role in the extensive crosstalk between O-GlcNAcylation and phosphorylation involved in cellular signalling.^[@bib92]^ Interestingly, VGLU1 was increased significantly in our proteomics and also the transcriptomic (PFC and HPC) screens. This protein has already been shown to be increased in bipolar disorder and major depressive disorder^[@bib93]^ and decreased in schizophrenia.^[@bib94]^

We also tested proteins that have already been implicated at the pathway level in major psychiatric symptoms observed in 22q11.2DS. The first of these was the mTOR pathway, which has been linked to autism spectrum disorder,^[@bib95],\ [@bib96],\ [@bib97]^ cognition^[@bib98],\ [@bib99]^ and glutamate signalling.^[@bib100],\ [@bib101],\ [@bib102]^ The SRM analysis showed that mTOR was specifically affected in the PFC together with changes in the ERK1/2, PKCG and CAMK2 isoforms, which are essential components of NMDAR-related signal transduction. ERK is regulated by the activity of dopamine, serotonin and glutamate receptors.^[@bib103]^ ERK signalling has also been implicated in the mechanism of action of mood stabilizers^[@bib104]^ and antipsychotics^[@bib105]^ and has been shown to be affected in social behaviour^[@bib106]^ and autism spectrum disorder.^[@bib107],\ [@bib108],\ [@bib109]^

In contrast to the above findings, we found a robust increase in proteins relating to glutamatergic signalling in the HPC. This is consistent with the findings of the transcriptomic profiling study of the *Df(16)A*^*+/−*^ mouse, which found upregulation of a multimodal gene interaction network in the HPC associated with DLG4 and glutamatergic synapses.^[@bib5]^ The HPC has been implicated in the cognitive deficits in 22q11 as alterations in the gross morphology of this brain region have been observed in 22q11.2DS patients,^[@bib110],\ [@bib111],\ [@bib112]^ and this positively correlates with cognitive impairment.^[@bib112]^ Interestingly, PKCG was also found to be increased in the HPC. Furthermore, O-GlcNAcylation of AMPA receptor GluA2 is associated with NMDA receptor and PKC-independent long-term depression in Ca3-Ca1 synapses.^[@bib113]^ Therefore, our findings of alterations in the levels of OGT1 support the possibility that disruption of O-GlcNAcylation pathways could be involved in cognitive dysfunction processes.

In conclusion, this is the first system-based study to identify proteomic and metabonomic abnormalities in a 22q11.2DS mouse model. The main effects were brain region specific and involved proteins associated with chromatin modulation pathways, along with alterations in lipid and energy metabolism pathways. As one of the most robust candidates, we were able to identify OGT1, a potential miR-185 target, and postulated that O-GlcNAc might have effects on many of the affected pathways. These results provide further insights into the molecular basis of the synaptic, circuitry and behavioural deficits of the 22q11.1 mouse model and potentially of the human syndrome. A shortcoming of this study is that the employed approaches focus on global changes of FC and HPC tissue, although these brain regions are comprised of different subpopulations of brain cells, which might lead to a dilution of the magnitude of the changes. Further analysis into these brain regions and of the role of OGT1 in these effects might help to elucidate its neuronal functions and increase our understanding of the development and pathogenesis of schizophrenia and other psychiatric disorders in 22q11.2DS and in the wider population.
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![(**a**) Venn diagrams of the overlap of all identified proteins (left) and of all significantly altered proteins (right) identified in label-free LC-MS^E^ (liquid chromatography--mass spectrometry) proteomic profiling studies of *Df(16)A*^+/−^ mice compared with *wild-type* mice ([Supplementary Table S4](#sup1){ref-type="supplementary-material"} for full list). (**b**) Percentages of significantly increased (red) and decreased (green) proteins in *Df(16)A*^+/−^ mice across all proteomic studies. Mean percentages show significantly increased protein levels in the prefrontal cortex (PFC; *p*\<0.05, *t*-test). PFC combined are samples from both cohorts combined and in-gel digested (see Material and methods). As the hippocampal (HPC) was only investigated from one cohort, significant levels could not be established. (**c**) Top ingenuity pathway analysis: altered pathways in the PFC and HPC. (**d**) Detailed information of the overlapping proteins identified as significantly changing across all proteomic screens. Proteins were sorted by the number of proteomic studies in which they have been detected as significantly altered. Only proteins with a mean ratio of \>1.1 or \<0.9 across all identified studies are displayed. *P*-values were determined using MSstats and corrected to control for multiple hypothesis testing after Benjamini--Hochberg.^[@bib114]^ ([Supplementary Table S3](#sup1){ref-type="supplementary-material"} for full information). Proteins identified by one peptide (italic) were included if they were overlapping between the proteomic screens. Results were compared with the transcriptomic results using Affymetrix chips published by Stark *et al.*^[@bib5]^ and Feneleon *et al.*^[@bib11]^ Stark reported 716 transcripts altered in the FC and 85 transcripts in the HPC (false-discovery rate=0.01). Significantly changed transcripts are marked with an ▴ and ▾ according to their reported fold change direction in comparison to *wild-type* mice. Four different bioinformatic miRNA target prediction tools were used to assess if the upregulated proteins are potential Mir-185 targets. Xof4, predicted in X of the four predictions; D, downregulation; PC, positive control.](mp201627f1){#fig1}

![Significantly enriched pathways identified by gene set enrichment analysis using GO*stats* (proteins per pathway \>3). The top 15 significant Gene Ontotlogy (GO) terms are displayed. GO terms falling into the category of chromosomal regulation are highlighted in grey. A full colour version of this figure is available at the *Molecular Psychiatry* journal online.](mp201627f2){#fig2}

![Schematic model summarizing the findings of the proteomic and metabonomic profiling analyses. Green boxes: altered levels of molecules determined by proteomic or metabonomic profiling. Orange boxes: altered pathways determined by *in silico* pathway analysis using IPKB or gene set enrichment analysis. Increased levels of O-GlcNAc transferase subunit p110 (OGT1) lead to abnormal O-GlcNAcylation, which affects chromatin remodelling and transcriptional regulation. Levels of the OGT1 substrate UDP-GlcNac are generated by glycolysis and gluconeogenesis (both found to be enriched). Both glutamatergic and Ca^2+^ signalling are mainly affected in the hippocampus (HPC). (R)=regulates. IPKB, Ingenuity Protein Knowledge Base; PFC, prefrontal cortex.](mp201627f3){#fig3}

###### Differentially altered metabolites identified by metabolic profiling of PFC and HPC brain tissue from *Df(16)A* ^*+/−*^ mice (11 vs 10)

  *mz_Rt pair*        *Ion mode*  *HMDB/Chempub ID*     *Name*                                                                           *Class/function*                          *Exact mass*        *Delta (mz−exact mass)*   *MS/MS*   *Ratio*   P*-value*
  ------------------ ------------ --------------------- -------------------------------------------------------------------------------- ----------------------------------------- ------------------- ------------------------- --------- --------- -----------
  *Frontal cortex*                                                                                                                                                                                                                                   
   645.5_1323             \+      LMSP03020039          PE-Cer(d14:2(4E,6E)/19:0) PE-Cer(d15:2(4E,6E)/18:0)                              Ceramide phosphoethanolamines (SP0302)    644.4893            6.5E-05                   ID        0.64      0.0001
   426.4_681              \+      HMDB06464 HMDB05065   Elaidic carnitine Oleoylcarnitine                                                Acyl carnitine                            425.3505            4.5E-03                   ID        0.59      0.0101
   232.2_270              \+      HMDB02013             Butyrylcarnitine                                                                 Acyl carnitine                            231.147             4.4E-03                   ID        0.33      0.0133
   448.3_667              \+      74380333 123060515    *N*-docosanoyl taurine *N*-stearoyl tyrosine                                     *N*-acyl amine *N*-acyl amine             447.3382 447.3349   4.0E-04 3.7E-03           NP        0.70      0.0133
   765.6_1179             \+      123064881             PG(O-20:0/16:0)/PG(O-16:0/20:0)                                                  Glycerophosphoglycerol                    764.5931            1.6E-03                   ID        0.69      0.0220
   367.1_609              \+      8439                  Salicin 6-phosphate                                                              Glycoside phosphate                       366.0716            3.0E-03                   NP        1.44      0.0350
   650.4_1019             \+      135642574             PC(16:0/9:0(CHO))                                                                Phophatidylcholine                        649.4319            4.5E-03                   NP        0.71      0.0350
   530.5_1146             \+      \-                    Water loss from \#16 (548.5, 1146sec)                                            ---                                       ---                 ---                       ID        0.58      0.0350
   130_25                 \+      HMDB33561             2-Acetyl-4,5-dihydrothiazole                                                     ---                                       129.0248            1.4E-03                   NP        0.70      0.0435
   184.1_1095             \+      HMDB33141             Fragment of a phosphatidylcholine                                                ---                                       183.0796            5.0E-04                   ID        1.33      0.0435
   550.6_1035             \+      LMSP00000005          Cer(m18:1(4E)/18:0)                                                              Ceramide/sphingolipid                     549.5485            0.00013                   ID        0.55      0.0435
   631.6_1302             \+      LMSP03020003          PE-Cer(d14:1(4E)/18:1(9Z))/PE-Cer(d14:2(4E,6E)/18:0)/PE-Cer(d16:2(4E,6E)/16:0)   Ceramide phosphoethanolamines             630.4737            0.00022                   ID        0.68      0.0435
   252.1_526              \+      HMDB00101             Deoxyadenosine                                                                   Purine nucleosides and analogues          251.101             0.00412                   NP        2.62      0.0435
   643.5_1269             \+      HMDB07312             DG(18:3(9Z,12Z,15Z)/20:2(11Z,14Z)/0:0)(iso2) (several)                           Diacylglycerol                            642.5223            9.8E-03                   NP        0.60      0.0435
                                                                                                                                                                                                                                                      
  *Hippocampus*                                                                                                                                                                                                                                      
   382.3_619              \+      4266008 24701448      Prostaglandin F2 alpha dimethyl amide 5,6-DiHETrE-EA (several)                   Prostaglandin Endocannabinoid             381.2879            5.8E-03                   NP        0.39      0.0033
   771.6_1472             \+      123068775 123067209   SM(d18:2/21:0) PA(O-20:0/22:2(13Z,16Z))                                          Ceramide posphocholine Glycerophosphate   770.6302 770.6189   4.5E-03 6.8E-03           NP NP     0.57      0.0229
   359.2_661              \+      HMDB12983             Kinetensin 1-3                                                                   Peptide                                   358.2329            5.9E-03                   NP        0.56      0.031
   799.7_1372             \+      123068785             SM(d17:1/24:1) or SM(d18:2/23:0)                                                 Sphingomyelin                             798.6615            7.8E-03                   ID        1.72      0.031
   360.3_662              \+      ---                   S-palmitoyl-L-cysteine                                                           Palmitoylated residue                     359.2494            5.7E-03                   NP        0.59      0.031
   140.1_1645             \+      207572 5035           4-Amino-5-hydroxymethyl-2-methylpyrimidine L-Histidinal                          Thiamin metabolism Histidin metabolism    139.0746            1.7E-04                   NP        0.35      0.042
   545.3_725              \+      ---                   PC (no database match, Isotope of 544.3 (PC 20:4))                               Phophatidylcholine                        ---                 ---                       T         0.67      0.042
   882.6_1302             \+      123061384             PC(22:5(4Z,7Z,10Z,13Z,16Z)/22:5(4Z,7Z,10Z,13Z,16Z))                              Phophatidylcholine                        881.5935            7.7E-03                   NP        0.69      0.042
   479.3_760             ---      ---                   Phospholipid---ID cannot be confirmed                                            ---                                       ---                 ---                       T         0.55      3E-05
   218.1_300             ---      149588                Pantothenic acid                                                                 Vitamine                                  219.1107            4.6E-05                   NP        0.80      0.019
   194.1_632             ---      HMDB14903 HMDB29217   Metyrosine Tyrosine methylester                                                  Tyrosine                                  195.0895            2.3E-04                   NP        0.61      0.023
   566.3_758             ---      LMGP01050056          PC(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/0:0)                                              Glycerophosphocholine                     567.3325            3.2E-05                   ID        1.30      0.023
   567.3_758             ---      LMGP01050056          Isotope of 566.3_758                                                                                                                                                                          
   480.3_746             ---      LMGP01060010          PC(O-16:0/0:0)                                                                   Phosphatidylcholine                       481.3532            −7.8E-05                  ID        1.43      0.043
   532.3_815             ---      LMSP02010055          Cer(d14:2(4E,6E)/20:1(11Z))                                                      *N*-acylsphingosines (ceramides)          533.4808            -0.0003                   ID        0.66      0.043

Abbreviations: HFC, hippocampus; ID, identified; MS/MS, tandem mass spectrometry; NP, cannot (dis)prove ID; PFC, prefrontal cortex; T, tentative, class indicated but not database match. Databank searches in METLIN, Lipidmaps, HMDB and MS/MS fragmentation were employed for metabolite identification.

###### Significantly changed proteins identified using label-based LC-SRM (targeted proteomics) in the PFC and HPC of the *Df(16)A* ^+/−^ mouse compared with *wild-type* mice (PFC=20 vs 20, HPC=11 vs 10)

                                                                                                                                                                                                                                          *Prefrontal cortex*   *Hippocampus*                                                                                     
  -------------------------------------------------------------------- ---------- --------------------------------------------------------------- ----------- ----------------------------------------------------------- ------ ------- --------------------- --------------- ----- -------- ----------- ----------- ------- ------- ------ -------- ----------- -----------
  *22q11.2 critical gene products+vector construct*                                                                                                                                                                                                                                                                                                               
  * Sep-05*                                                             *Q9Z2Q6*  *Septin-5*                                                      *Sep-05*    *22q11.2*                                                    *⇓*   *▾*              *▾*                *▾*        *▾*   *0.78*   *5.2E-11*   *1.1E-09*    *⇓*     *▾*    *▾*    *0.85*   *1.8E-04*   *4.9E-04*
  * RANG*                                                               *P34022*  *Ran-specific GTPase-activating protein*                        *Ranbp1*    *22q11.2*                                                    *⇓*   *---*           *---*              *---*       *▾*   *0.55*   *\<E-15*    *\<E-15*     *⇓*    *---*   *▾*    *0.47*   *\<E-15*    *\<E-15*
  * Q8JZU2*                                                             *Q8JZU2*  *Protein Slc25a1*                                               *Slc25a1*   *22q11.2*                                                    *⇓*   *---*           *---*              *---*       *▾*   *0.79*   *4.8E-08*   *7.5E-07*    *⇓*    *---*   *▾*    *0.64*   *6.7E-10*   *5.9E-09*
  * PROD*                                                               *Q9WU79*  *Proline dehydrogenase 1, mitochondrial*                        *Prodh*     *22q11.2*                                                    *⇓*   *---*           *---*              *---*       *▾*   *0.62*   *3.5E-07*   *4.4E-06*    *⇓*    *---*   *▾*    *0.90*    *0.26*      *0.30*
  * COMT*                                                               *O88587*  *Catechol O-methyltransferase*                                  *Comt*      *22q11.2*                                                    *⇓*   *---*           *---*              *---*       *▾*   *0.76*   *1.4E-06*   *1.4E-05*    *⇓*    *---*   *▾*    *0.71*   *1.6E-03*   *3.6E-03*
  * HPRT*                                                               *P00493*  *Hypoxanthine-guanine phosphoribosyltransferase*                *Hprt1*     *Vector construct*                                           *\**  *▴*             *---*              *---*       *▴*   *1.56*   *\<E-15*    *\<E-15*    *---*   *---*   *▾*    *1.77*   *\<E-15*    *\<E-15*
                                                                                                                                                                                                                                                                                                                                                                        
  *miRNA targets*                                                                                                                                                                                                                                                                                                                                                 
  * GSK3B*                                                              *Q9WV60*  *Glycogen synthase kinase-3 beta*                               *Gsk3b*     *miRNA target (2/4)*                                         *⇑*   *NS*            *---*               *▾*        *▴*   *1.14*    *4E-06*    *3.2E-05*   *NS*    *---*   *▴*    *1.16*   *6.1E-04*   *1.5E-03*
  * OGT1*                                                               *Q8CGY8*  *O-GlcNAc transferase subunit p110*                             *Ogt*       *miRNA target (1/4) + [Figure 1d](#fig1){ref-type="fig"}*    *⇑*   *▴*             *---*              *---*       *▴*   *1.22*   *1.3E-02*   *3.5E-02*   *NS*    *---*   *▴*    *1.20*   *8.9E-03*   *1.6E-02*
  * KIF5A*                                                              *P33175*  *Kinesin heavy chain isoform 5A*                                *Kif5a*     *miRNA target (1/4)*                                         *NS*  *---*           *---*               *▴*        *▴*   *1.22*   *3.6E-02*    *0.09*      *⇑*    *---*   *NS*   *1.15*    *0.18*      *0.22*
   A4                                                                    P12023   Amyloid beta A4 protein                                         App         miRNA target (1/4)                                            NS   ---              ---                ---        NS     1.13     6.5E-02      0.13       NS      ---     NS     1.11      0.16        0.21
   KDM2A                                                                 P59997   Lysine-specific demethylase 2A                                  Kdm2a       miRNA target (2/4)                                            NS   ---              ---                ---        NS     1.02      0.77        0.86       NS      ---     NS     1.06      0.71        0.74
   RHOA                                                                  Q9QUI0   Transforming protein RhoA                                       Rhoa        miRNA target, Liu *et al.,*^[@bib115]^                        NS   NS               NS                 NS         NS     1.05      0.37        0.48       NS       ▾      NS     1.08      0.05        0.08
   MBOA5                                                                 Q91V01   Lysophospholipid acyltransferase 5                              Lpcat3      miRNA target (1/4) + [Figure 1d](#fig1){ref-type="fig"}       NS   ---              ---                ---        NS     1.09      0.13        0.21       NS      ---     NS     ---        ---         ---
   ADA10                                                                 O35598   Disintegrin metalloproteinase domain-containing protein 10      Adam10      miRNA target (3/4)                                            NS   (▴)              ---                ---        NS     1.03      0.59        0.73       NS      NS      NS     1.04      0.696      0.7443
   ANFY1                                                                 Q810B6   Ankyrin repeat and FYVE domain-containing protein 1             Ankfy1      miRNA target (1/4)                                            NS   ---              ---                ---        NS     1.02      0.85        0.91       NS      NS      NS     1.22      0.05        0.07
                                                                                                                                                                                                                                                                                                                                                                        
  *Discovery*                                                                                                                                                                                                                                                                                                                                                     
  * PP2BC*                                                              *P48455*  *Serine/threonine-protein phosphatase 2B catalytic γ isoform*   *Ppp3cc*    *[Figure 1d](#fig1){ref-type="fig"}*                         *NS*  *▴*              *▴*                *▴*        *▴*   *1.06*   *1.1E-02*   *3.1E-02*    NS      NS      ▴      1.21     4.7E-10     4.8E-09
   PP2BB                                                                 P48453   Serine/threonine-protein phosphatase 2B catalytic β isoform     Ppp3cb                                                                    NS   NS               NS                 NS          ▴     1.16     5.8E-04     2.4E-03     NS      NS      ▴      1.16     8.9E-03     1.6E-02
  * NFL*                                                                *P08551*  *Neurofilament light polypeptide (NF-L)*                        *Nefl*      *[Figure 1d](#fig1){ref-type="fig"}*                          NS   *▴*              \-                 *▴*        *▴*   *1.09*   *1.8E-03*   *6.3E-03*    NS      NS      ▴      1.15     1.6E-04     4.9E-04
   AINX                                                                  P46660   Alpha-internexin (Alpha-Inx)                                    Ina         [Figure 1d](#fig1){ref-type="fig"}                            NS   ▴                ---                 ▴         NS     0.96      0.31        0.42       NS      NS      ▴      1.21     3.0E-08     2.3E-07
   NRDC                                                                  Q8BHG1   Nardilysin (EC 3.4.24.61)                                       Nrd1        [Figure 1d](#fig1){ref-type="fig"}                            NS   ---               ▾                  ▾         NS     1.02      0.60        0.73       NS      NS      NS     0.99      0.89        0.90
  * VGLU1*                                                              *Q3TXX4*  *Vesicular glutamate transporter 1 (VGluT1)*                    *Slc17a7*   *Transcriptomics*^[@bib5]^                                   *⇑*   *NS*            *---*              *---*       *▴*   *1.16*   *1.6E-06*   *1.4E-05*    *⇑*    *NS*    *▴*    *1.19*   *1.5E-04*   *4.8E-04*
                                                                                                                                                                                                                                                                                                                                                                        
  *Implicated pathways*                                                                                                                                                                                                                                                                                                                                           
   *mTOR--autism spectrum disorders and mental retardation*                                                                                                                                                                                                                                                                                                       
    MTOR                                                                 Q9JLN9   Serine/threonine-protein kinase mTOR                            Mtor                                                                     *NS*  *---*           *---*              *---*       *▴*   *1.28*   *4.8E-04*   *2.1E-03*    NS      NS      NS     1.10      0.30        0.34
    MK03                                                                 Q63844   Mitogen-activated protein kinase 3 (ERK-1)                      Mapk3                                                                    *NS*  *▴*             *---*              *---*       *▴*   *1.16*   *2.3E-05*   *1.5E-04*    NS      NS      ▴      1.23     3.7E-05     1.3E-04
    MK01                                                                 P63085   Mitogen-activated protein kinase 1 (ERK-2)                      Mapk1                                                                    *NS*  *▴*             *---*              *---*       *▴*   *1.11*   *5.9E-05*   *3.0E-04*    NS      NS      ▴      1.07     6.3E-03     1.2E-02
    PEA15                                                                Q62048   Astrocytic phosphoprotein PEA-15                                Pea15                                                                    *NS*  *▴*             *---*              *---*       *▴*   *1.15*   *5.0E-05*   *2.8E-04*    NS      ---     ▾      0.91     2.8E-02     4.4E-02
    KPCG                                                                 P63318   Protein kinase C gamma type                                     Prkcg                                                                    *⇑*   *(▴)*           *NS*               *NS*        *▴*   *1.11*   *1.2E-03*   *4.6E-03*    NS      NS      ▴      1.21     6.2E-07     2.9E-06
                                                                                                                                                                                                                                                                                                                                                                        
  *Glutamatergic signalling---schizophrenia and affective disorders*                                                                                                                                                                                                                                                                                              
   NMDZ1                                                                 P35438   Glutamate receptor ionotropic, NMDA 1 (NMD-R1)                  Grin1       Hippocampus network^[@bib5]^                                  NS   ---              ---                ---         ▴     1.15      0.015      3.8E-02     *⇑*    *NS*    *▴*    *1.86*   *1.1E-12*   *2.3E-11*
   GRIA1                                                                 P23818   Glutamate receptor 1 (GluR-1)                                   Gria1       Hippocampus network^[@bib5]^                                  ⇑    NS               ---                ---        NS     1.08      0.18        0.26       *⇑*    *NS*    *▴*    *1.43*   *2.7E-06*   *1.0E-05*
   GRIA2                                                                 P23819   Glutamate receptor 2 (GluR-2)                                   Gria2                                                                     NS   ---              NS                 (▴)         ▴     1.12      4E-04       2E-03      NS       ▾      ▴      1.25     1.9E-12     2.9E-11
   GRIA3                                                                 Q9Z2W9   Glutamate receptor 3 (GluR-3)                                   Gria3       Hippocampus network^[@bib5]^                                  NS   ---              NS                 ---        NS     1.03      0.64        0.76       *⇑*    *---*   *▴*    *1.30*   *1.1E-03*   *2.6E-03*
   KCC2A                                                                 P11798   Calcium/calmodulin-dependent protein kinase type II α           Camk2a      Hippocampus network^[@bib5]^                                  ⇑    NS                ▴                 ---        NS     1.05      0.20        0.28       *⇑*    *NS*    *▴*    *1.27*   *1.6E-07*   *1.1E-06*
   KCC2G                                                                 Q923T9   Calcium/calmodulin-dependent protein kinase type II γ           Camk2g                                                                    NS   NS               NS                 NS         NS     1.05      0.11        0.20       NS      NS      ▴      1.25     1.7E-04     4.9E-04
   SYT1                                                                  P46096   Synaptotagmin-1                                                 Syt1        Hippocampus network^[@bib5]^                                  NS   NS                ▾                  ▴         NS     1.05      0.07        0.13       *⇑*    *NS*    *NS*   *1.08*    *0.05*      *0.08*
   DLG4                                                                  Q62108   Disks large homolog 4                                           Dlg4        Hippocampus network^[@bib5]^                                  ⇑    ---              ---                NS         NS     1.00      0.81        0.88       *⇑*    *NS*    *▴*    *1.17*   *7.6E-05*   *2.6E-04*
   NCDN                                                                  Q9Z0E0   Neurochondrin (Norbin)                                          Ncdn                                                                      ⇑    NS               NS                  ▴         (▴)    1.09      0.05        0.10      *NS*    *NS*    *▴*    *1.27*   *3.0E-03*   *6.2E-03*
                                                                                                                                                                                                                                                                                                                                                                        
  *Housekeeping*                                                                                                                                                                                                                                                                                                                                                  
   RL8                                                                   P62918   60S ribosomal protein L8                                        Rpl8                                                                      ⇓    ---              ---                ---        NS     1.05      0.35        0.46       NS      NS     ---     ---        ---         ---
   MAP2                                                                  O08663   Methionine aminopeptidase 2                                     Metap2                                                                    NS   NS               NS                 NS         NS     1.04      0.21        0.29       NS      NS      NS     1.06      0.04        0.06
   RS3A                                                                  P97351   40S ribosomal protein S3a                                       Rps3a                                                                     NS   ---              ---                ---        NS     1.04      0.11        0.20       NS      NS     (▴)     1.12      0.04        0.06

Abbreviations: HFC, hippocampus; NS, not significant. Significantly (*P*\*\<0.05) downregulated and upregulated in proteomic profiling (▾▴) or transcriptomic profiling^[@bib5],\ [@bib8]^ (⇑⇓), in brackets if only *P*\<0.05; PFC, prefrontal cortex; ---, not detected.

Findings are compared with label-free LC-MS^E^ proteomic discovery profiling and transcriptomic profiling results. Italicized cells indicates consistency across the studies. Column 'Label\' indicates implication of protein (for example, predicted miRNA target by Xof4 bioinformatic prediction tools). *P*-values were determined using SRM*stats* and corrected for multiple hypothesis testing (*P*\*).^[@bib18]^
